Quantbot Technologies LP Cuts Stake in Eli Lilly and Company $LLY

Quantbot Technologies LP decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 57.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,480 shares of the company’s stock after selling 3,411 shares during the period. Quantbot Technologies LP’s holdings in Eli Lilly and Company were worth $1,892,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sumitomo Mitsui Financial Group Inc. acquired a new stake in Eli Lilly and Company in the second quarter valued at approximately $27,000. Evolution Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the 2nd quarter worth about $29,000. Steph & Co. increased its holdings in shares of Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after acquiring an additional 29 shares during the last quarter. Financial Gravity Companies Inc. purchased a new stake in Eli Lilly and Company during the second quarter worth approximately $31,000. Finally, Bare Financial Services Inc boosted its holdings in Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 29 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 0.4%

LLY stock opened at $1,004.12 on Thursday. The stock has a market capitalization of $947.25 billion, a PE ratio of 43.75, a price-to-earnings-growth ratio of 1.17 and a beta of 0.40. The company has a fifty day moving average of $1,049.25 and a 200-day moving average of $936.91. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same period in the prior year, the company posted $5.32 earnings per share. The firm’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is presently 30.15%.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent analyst reports. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 2nd. Royal Bank Of Canada assumed coverage on shares of Eli Lilly and Company in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 price objective for the company. TD Cowen lifted their target price on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 31st. Finally, Barclays initiated coverage on Eli Lilly and Company in a research note on Thursday, February 19th. They issued an “overweight” rating and a $1,350.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,229.59.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Shareholders approved Eli Lilly’s acquisition of Ventyx Biosciences, clearing a regulatory/transactional hurdle that extends Lilly’s pipeline and inorganic growth options. Ventyx Merger Approved
• Positive Sentiment: Lilly advanced remternetug (an Alzheimer’s asset) testing in China, broadening its geographic trial footprint and potentially improving future market access in a key region for neurodegenerative therapies. Remternetug China Trial Update
• Positive Sentiment: Lilly progressed a new oral diabetes candidate in China (Phase 1 update), supporting continued expansion of its diabetes/GLP-1 franchise beyond injectable offerings. Pipeline diversification can support longer-term revenue growth. Oral Diabetes Drug in China
• Positive Sentiment: Analyst/market commentary (Zacks) flags Lilly as a strong momentum name and notes elevated investor attention—coverage that can support continued flows and multiple expansion if momentum resumes. Zacks Momentum Coverage
• Neutral Sentiment: The DIA 2026 Global Annual Meeting will bring cross-sector life-sciences attention to product development themes; this is industry-positive but not a direct LLY catalyst. DIA 2026 Meeting
• Neutral Sentiment: Broader market rotation stories (e.g., articles arguing biotech is outperforming AI) could redirect funds into pharma/biotech, a potential tailwind but uncertain for any single name. Biotech vs AI Rotation
• Neutral Sentiment: Competitor/sector updates (e.g., J&J immunology & neuroscience growth) highlight competitive dynamics in immunology/neuroscience but are not an immediate direct hit to Lilly’s headline momentum. JNJ Sector Update
• Negative Sentiment: Valuation and momentum checks note cooling short-term performance after years of strong gains; concerns about stretched multiples are pressuring sentiment and limiting upside near term. Valuation Check
• Negative Sentiment: Some retail/investing commentary recommends reallocating from Lilly into other “unstoppable” stocks, creating narrative-driven outflows and headline risk for momentum investors. Fool: Alternatives to Lilly

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.